Evidence map›Paper›PMID 35574953›Full record

ArticleJournal of the American Heart Association2022

Ultrashort Door-to-Needle Time for Intravenous Thrombolysis Is Safer and Improves Outcome in the Czech Republic: Nationwide Study 2004 to 2019.

Robert Mikulík, Michal Bar, Silvie Bělašková, David Černík, Jan Fiksa, Roman Herzig, René Jura, Lubomír Jurák, Lukáš Klečka, Jiří Neumann and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Robert MikulíkInternational Clinical Research Center and Department of Neurology St. Anne's University Hospital in Brno Czech Republic.ORCID 0000-0002-7458-5166
Michal BarDepartment of Neurology University Hospital Ostrava and Faculty of Medicine at University Ostrava Ostrava Czech Republic.ORCID 0000-0002-5049-5844
Silvie BělaškováInternational Clinical Research Center and Department of Neurology St. Anne's University Hospital in Brno Czech Republic.
David ČerníkComprehensive Stroke Center - Department of Neurology Masaryk Hospital Ustí nad Labem - KZ a.s. Ustí nad Labem Czech Republic.ORCID 0000-0003-4005-804X
Jan FiksaDepartment of Neurology First Faculty of Medicine and General University Hospital, Charles University Prague Czech Republic.ORCID 0000-0002-5748-0127
Roman HerzigComprehensive Stroke Center University Hospital Hradec KrálovéCharles University Faculty of Medicine in Hradec Králové Czech Republic.ORCID 0000-0001-7238-7724
René JuraFaculty of Medicine at Masaryk University Brno Czech Republic.ORCID 0000-0002-0361-0256
Lubomír JurákNeurocenter Regional Hospital Liberec Liberec Czech Republic.ORCID 0000-0002-2096-2798
Lukáš KlečkaDepartment of Neurology Town Hospital Ostrava Ostrava Czech Republic.ORCID 0000-0002-1316-5782
Jiří NeumannDepartment of Neurology Chomutov Hospital, KZ a.s. Chomutov Czech Republic.ORCID 0000-0003-4857-6618
Svatopluk OstrýComprehensive Stroke Center Hospital České Budějovice, a.s. České Budějovice Czech Republic.ORCID 0000-0003-1858-7922
Daniel ŠaňákComprehensive Stroke Center in Department of Neurology Palacký Medical School and University Hospital Olomouc Czech Republic.ORCID 0000-0001-5426-1810
Petr ŠevčíkDepartment of Neurology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic.ORCID 0000-0002-5309-7446
Ondřej ŠkodaDepartment of Neurology Hospital Jihlava Jihlava Czech Republic.
Martin ŠrámekDepartment of Neurology Central Military University Hospital Prague and Motol University Hospital Prague Czech Republic.ORCID 0000-0002-5519-9876
Aleš TomekDepartment of Neurology 2nd Medical School of Charles University and Motol University Hospital Prague Czech Republic.ORCID 0000-0002-7468-499X
Daniel VáclavíkDepartment of Neurology and AGEL Research and Training Institute Ostrava Vítkovice Hospital Ostrava Czech Republic.ORCID 0000-0002-1902-1093
Czech Stroke Unit Network
Charles University · CZMasaryk University · CZKrajská Nemocnice Liberec · CZKrajská Zdravotní · CZMilitary University Hospital Prague · CZStrix Chomutov (Czechia) · CZUniversity Hospital Brno · CZUniversity Hospital Olomouc · CZUniversity Hospital Ostrava · CZUniversity of Ostrava · CZVitkovice - Research and Development (Czechia) · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The benefit of intravenous thrombolysis is time dependent. It remains unclear, however, whether dramatic shortening of door-to-needle time (DNT) among different types of hospitals nationwide does not compromise safety and still improves outcome. Methods and Results Multifaceted intervention to shorten DNT was introduced at a national level, and prospectively collected data from a registry between 2004 and 2019 were analyzed. Generalized estimating equation was used to identify the association between DNT and outcomes independently from prespecified baseline variables. The primary outcome was modified Rankin score 0 to 1 at 3 months, and secondary outcomes were parenchymal hemorrhage/intracerebral hemorrhage (ICH), any ICH, and death. Of 31 316 patients treated with intravenous thrombolysis alone, 18 861 (60%) had available data: age 70±13 years, National Institutes of Health Stroke Scale at baseline (median, 8; interquartile range, 5-14), and 45% men. DNT groups 0 to 20 minutes, 21 to 40 minutes, 41 to 60 minutes, and >60 minutes had 3536 (19%), 5333 (28%), 4856 (26%), and 5136 (27%) patients. National median DNT dropped from 74 minutes in 2004 to 22 minutes in 2019. Shorter DNT had proportional benefit: it increased the odds of achieving modified Rankin score 0 to 1 and decreased the odds of parenchymal hemorrhage/ICH, any ICH, and mortality. Patients with DNT ≤20 minutes, 21 to 40 minutes, and 41 to 60 minutes as compared with DNT >60 minutes had adjusted odds ratios for modified Rankin score 0 to 1 of the following: 1.30 (95% CI, 1.12-1.51), 1.33 (95% CI, 1.15-1.54), and 1.15 (95% CI, 1.02-1.29), and for parenchymal hemorrhage/ICH: 0.57 (95% CI, 0.45-0.71), 0.76 (95% CI, 0.61-0.94), 0.83 (95% CI, 0.70-0.99), respectively. Conclusions Ultrashort initiation of thrombolysis is feasible, improves outcome, and makes treatments safer because of fewer intracerebral hemorrhages. Stroke management should be optimized to initiate thrombolysis as soon as possible optimally within 20 minutes from arrival to a hospital.

Indexed as

Brain IschemiaStrokeAdministration, IntravenousAgedAged, 80 and overCerebral HemorrhageCzech RepublicFemaleFibrinolytic AgentsHumansMaleMiddle AgedThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeFibrinolytic AgentsTissue Plasminogen Activatoracute ischemic strokedoor‐to‐needle timeintravenous thrombolysisstroke logistics

Identifiers

PMID35574953
PMCPMC9238542
OpenAlexW4280520087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.